Michael von Forstner | Global Head, Safety Science
Sobi (Swedish Orphan Biovitrum)

Michael von Forstner is a seasoned leader in drug safety and pharmacovigilance. With 25 years of experience in the pharmaceutical industry, Michael has a proven track record of driving strategic innovation, leveraging technology, and enhancing performance in pharmacovigilance and patient safety. Throughout his career, Michael has been at the forefront of developing and implementing cutting-edge safety strategies to ensure the well-being of patients and the compliance of pharmaceutical products with regulatory standards. His most recent core interest lies in harnessing the power of real-world data and evidence, data analytics, artificial intelligence, and digital solutions in combination with the elucidation of patient preferences for efficacy and safety outcomes, to optimize benefit-risk management processes and improve risk management practices.

Michael is a dynamic and engaging speaker who is passionate about sharing his knowledge and insights with fellow safety professionals and industry partners. His presentations are known for their practicality, relevance, and thought-provoking perspectives on the evolving landscape of drug safety.

At the World Drug Safety Congress Americas 2025, Michael will be discussing the latest trends in global approaches to benefit-risk management practices, taking into account learnings from the implementation of recent guidances from the EMA, the FDA, and CIOMS.

With his deep understanding of safety science, commitment to continuous improvement, and strategic vision for the future of drug safety, Michael von Forstner is a valuable asset to any organization looking to elevate its patient safety and pharmacovigilance strategies and their operational implementation, and deliver safer healthcare solutions to patients worldwide.